Switch theme
Sign up to access all valuation multiples
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.
1997
250
LTM Revenue $110M
LTM EBITDA -$193M
$220M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Xencor has a last 12-month revenue (LTM) of $110M and a last 12-month EBITDA of -$193M.
In the most recent fiscal year, Xencor achieved revenue of $110M and an EBITDA of -$186M.
Xencor expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Xencor valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $110M | XXX | $110M | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$193M | XXX | -$186M | XXX | XXX | XXX |
| EBITDA Margin | -175% | XXX | -168% | XXX | XXX | XXX |
| EBIT | -$194M | XXX | -$178M | XXX | XXX | XXX |
| EBIT Margin | -176% | XXX | -161% | XXX | XXX | XXX |
| Net Profit | -$220M | XXX | -$233M | XXX | XXX | XXX |
| Net Margin | -200% | XXX | -211% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $123M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 31, 2025, Xencor's stock price is $9.
Xencor has current market cap of $621M, and EV of $220M.
See Xencor trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $220M | $621M | XXX | XXX | XXX | XXX | $-3.20 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 31, 2025, Xencor has market cap of $621M and EV of $220M.
Xencor's trades at 2.0x EV/Revenue multiple, and -1.2x EV/EBITDA.
Equity research analysts estimate Xencor's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Xencor has a P/E ratio of -2.8x.
See valuation multiples for Xencor and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $621M | XXX | $621M | XXX | XXX | XXX |
| EV (current) | $220M | XXX | $220M | XXX | XXX | XXX |
| EV/Revenue | 2.0x | XXX | 2.0x | XXX | XXX | XXX |
| EV/EBITDA | -1.1x | XXX | -1.2x | XXX | XXX | XXX |
| EV/EBIT | -1.1x | XXX | -1.2x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -2.8x | XXX | -2.7x | XXX | XXX | XXX |
| EV/FCF | -2.4x | XXX | -1.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialXencor's last 12 month revenue growth is 18%
Xencor's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $1.2M for the same period.
Xencor's rule of 40 is -58% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Xencor's rule of X is -131% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Xencor and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 18% | XXX | 14% | XXX | XXX | XXX |
| EBITDA Margin | -175% | XXX | -168% | XXX | XXX | XXX |
| EBITDA Growth | -10% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -58% | XXX | -151% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -131% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 206% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 261% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Xencor acquired XXX companies to date.
Last acquisition by Xencor was XXXXXXXX, XXXXX XXXXX XXXXXX . Xencor acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Xencor founded? | Xencor was founded in 1997. |
| Where is Xencor headquartered? | Xencor is headquartered in United States of America. |
| How many employees does Xencor have? | As of today, Xencor has 250 employees. |
| Who is the CEO of Xencor? | Xencor's CEO is Dr. Bassil I. Dahiyat, PhD.. |
| Is Xencor publicy listed? | Yes, Xencor is a public company listed on NAS. |
| What is the stock symbol of Xencor? | Xencor trades under XNCR ticker. |
| When did Xencor go public? | Xencor went public in 2013. |
| Who are competitors of Xencor? | Similar companies to Xencor include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Xencor? | Xencor's current market cap is $621M |
| What is the current revenue of Xencor? | Xencor's last 12 months revenue is $110M. |
| What is the current revenue growth of Xencor? | Xencor revenue growth (NTM/LTM) is 18%. |
| What is the current EV/Revenue multiple of Xencor? | Current revenue multiple of Xencor is 2.0x. |
| Is Xencor profitable? | Yes, Xencor is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Xencor? | Xencor's last 12 months EBITDA is -$193M. |
| What is Xencor's EBITDA margin? | Xencor's last 12 months EBITDA margin is -175%. |
| What is the current EV/EBITDA multiple of Xencor? | Current EBITDA multiple of Xencor is -1.1x. |
| What is the current FCF of Xencor? | Xencor's last 12 months FCF is -$92.3M. |
| What is Xencor's FCF margin? | Xencor's last 12 months FCF margin is -84%. |
| What is the current EV/FCF multiple of Xencor? | Current FCF multiple of Xencor is -2.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
